Biopharmaceutical Development Articles & Analysis
9 articles found
Recombinant protein expression is a cornerstone of modern biopharmaceutical development, providing the means to produce proteins with therapeutic potential, enzymes, and antibodies. ...
Compared to protein drugs, peptide drugs also have advantages such as good stability, high purity, low production cost, and low immunogenicity. With the rapid development and maturity of peptide synthesis technology, peptide drugs have become the focus of biopharmaceutical research and development in recent years. ...
Bioproduction is a critical element in the creation of many vaccines, therapeutics, and other biopharmaceuticals. A central facet of this process involves the development of stable cell lines that are capable of producing these vital products in abundance and with consistency. ...
Host cell proteins (HCPs) are process-related impurities produced by host cells and are typically present at low levels in recombinant biopharmaceutical products. Enzyme-linked immunosorbent assay (ELISA) has traditionally been used to monitor the total content of HCP in the production of therapeutic protein drugs. ...
Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics. ...
Symberix co-founder Matt Redinbo also published a research article in PNAS in March 2020 describing microbiota-targeted therapeutics that inhibit gut bacterial β-glucuronidases to enhance anticancer drug efficacy. Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to treat lower GI ...
And their spin-off company, Symberix, is developing treatments to reduce side effects caused by gut bacteria.” Read the full Nature article here. Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to treat lower GI disorders. ...
As regulators focus in on the critical quality attributes (CQAs) of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations assays – other than to run additional orthogonal assays? ...
This paper analyses which organisational and industrial factors influence the chance that a US biopharmaceutical start-up is able to introduce a new drug on the US market. ...